Asian Tech Press (Sep 2) -- BioNTech partner Fosun Pharma said on Thursday that the first shipment of mRNA COVID-19 vaccine arrived in Taiwan.

Shanghai Fosun Pharmaceutical (Group) Co., Ltd. ("Fosun Pharma", 02196: HK) announced on Thursday that the first shipment of mRNA COVID-19 vaccine Fubitai (or BNT162b2), manufactured by German company BioNTech SE (NASDAQ: BNTX), supplied by Fosun Pharma to Taiwan, arrived at Taiwan Taoyuan International Airport from Europe, with the first 932,000 doses delivered.

The vaccine will be used to vaccinate people in Taiwan through a donation route from private institutions in Taiwan. It is indicated for active immunization of adolescents and adults aged 12 and above against diseases caused by novel coronavirus infections.

Wu Yifang, Chairman and CEO of Fosun Pharma, said, "We are pleased to see that this mRNA COVID-19 vaccine, co-developed by Fosun Pharma and BioNTech, will play an active role in the prevention and control of the epidemic for our compatriots in Taiwan and help them build an immune barrier against COVID-19."

On March 16, 2020, Fosun Pharma and BioNTech announced a strategic collaboration agreement to jointly develop and commercialize vaccine products against COVID-19 based on their proprietary mRNA technology platform in mainland China, Hong Kong, Macau and Taiwan.

In July 2021, Fosun Industrial Co., Ltd, a holding subsidiary of Fosun Pharma, entered into an advance procurement agreements for a total of 15 million doses of mRNA COVID-19 vaccine with parties including TSMC, Foxconn, YongLin Foundation, Tzu Chi Foundation and Zuellig Pharma.